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The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in
2012 and 2015, on the management of type 2 diabetes in adults. A systematic
evaluation of the literature since 2014 informed new recommendations. These
include additional focus on lifestyle management and diabetes self-management
education and support. For those with obesity, efforts targeting weight loss,
including lifestyle, medication, and surgical interventions, are recommended.With
regards to medication management, for patients with clinical cardiovascular
disease, a sodium–glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like
peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recom-
mended. For patients with chronic kidney disease or clinical heart failure and
atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is
recommended. GLP-1 receptor agonists are generally recommended as the first
injectable medication.
The goals of treatment for type 2 diabetes are to prevent or delay complications and
maintainquality of life (Fig. 1). This requires control ofglycemiaandcardiovascular risk
factormanagement, regular follow-up, and, importantly, apatient-centeredapproach
to enhance patient engagement in self-care activities (1). Careful consideration of
patient factors and preferences must inform the process of individualizing treatment
goals and strategies (2,3).
This consensus report addresses the approaches to management of glycemia in
adults with type 2 diabetes, with the goal of reducing complications and maintaining
quality of life in the context of comprehensive cardiovascular risk management and
patient-centered care. The principles of how this can be achieved are summarized in
Fig. 1 and underpin the approach to management and care. These recommendations
arenot generally applicable topatientswithmonogenic diabetes, secondarydiabetes,
or type 1 diabetes, or to children.
Data Sources, Searches, and Study Selection
The writing group accepted the 2012 (4) and 2015 (5) editions of this position
statement as a starting point. To identify newer evidence, a search was conducted on
PubMed for randomized clinical trials (RCTs), systematic reviews, and meta-analyses
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published in English between 1 January
2014 and 28 February 2018; eligible
publications examined the effectiveness
or safety of pharmacological or nonphar-
macological interventions in adults with
type 2 diabetes mellitus. Reference lists
were scanned in eligible reports to iden-
tify additional articles relevant to the sub-
ject. Details on the keywords and the
search strategy are available at https://
doi.org/10.17632/h5rcnxpk8w.1. Papers
were grouped according to subject, and
the authors reviewed this new evidence to
inform the consensus recommendations.
The draft consensus recommendations
were peer reviewed (see “Acknowledg-
ments”), and suggestions incorporated
as deemed appropriate by the authors.
Nevertheless, though evidence-based,
the recommendations presented herein
are the opinions of the authors.




nutrition therapy (MNT), physical activ-
ity, weight loss, counseling for smoking
cessation, and psychological support,
oftendelivered in the context of diabetes
self-management education and support
(DSMES), are fundamental aspects of
diabetes care. The expanding number
of glucose-lowering treatmentsdfrom
behavioral interventions to medica-
tions and surgerydand growing infor-
mation about their benefits and risks
provides more options for people with
diabetes and providers, but can compli-
cate decision making. In this consen-
sus statement, we attempt to provide
an approach that summarizes a large
body of recent evidence for practi-
tioners in the U.S. and Europe.
Marked hyperglycemia is associated
with symptoms including frequent uri-
nation, thirst, blurred vision, fatigue, and
recurring infections. Beyond alleviat-
ing symptoms, the aim of blood glu-
cose lowering (hereafter, referred to
as glycemic management) is to reduce
long-term complications of diabetes.
Good glycemic management yields sub-
stantial and enduring reductions in on-
set and progression of microvascular
complications. This benefit has been
demonstrated most clearly early in the
natural history of the disease in studies
using metformin, sulfonylureas, and in-
sulin but is supported by more recent
studies with other medication classes.
The greatest absolute risk reduction
(ARR) comes from improving poor gly-
cemic control, and a more modest re-
duction results from near normalization
of glycemia (6). The impact of glucose
control on macrovascular complica-
tions is less certain. Because the bene-
fits of intensive glucose control emerge
slowly, while the harms can be immedi-
ate, people with longer life expectancy
have more to gain from intensive glu-
cose control. A reasonable HbA1c target
for most nonpregnant adults with suffi-
cient life expectancy to see microvascu-
lar benefits (generally ;10 years) is
around 53 mmol/mol (7%) or less (6).
Glycemic treatment targets should be
individualized based on patient prefer-
ences and goals, risk of adverse effects
of therapy (e.g., hypoglycemia and
weight gain), and patient characteris-
tics, including frailty and comorbid
conditions (2).
Atherosclerotic cardiovascular dis-
ease (ASCVD) is the leading cause of
death in people with type 2 diabetes
(7). Diabetes confers substantial inde-
pendent ASCVD risk, and most people
with type 2 diabetes have additional risk
factors such as hypertension, dyslipide-
mia, obesity, physical inactivity, chronic
kidney disease (CKD), and smoking. Nu-
merous studies have demonstrated
the benefits of controlling modifiable
ASCVD risk factors in people with di-
abetes. Substantial reductions in ASCVD
events and death are seen when multi-
ple ASCVD risk factors are addressed
simultaneously, with long-standing ben-
efits (8,9). Comprehensive implementa-
tion of evidence-based interventions has
likely contributed to the significant re-
ductions in ASCVD events and mortality
seen in people with diabetes in recent
decades (10). ASCVD risk management
in its many forms is an essential part
of diabetes management that is beyond
the scope of this statement, but physi-
cians should be aware of the impor-
tance of multifactorial treatment in
type 2 diabetes (7).
Glucose Management: Monitoring
Glycemic management is primarily as-
sessedwith the HbA1c test, whichwas the
measure studied in trials demonstrating
the benefits of glucose lowering (2). The
performance of the test is generally
excellent for NGSP-certified assays and
laboratories (www.ngsp.org) (11). As
with any laboratory test, HbA1c has lim-
itations (2). Because there is variability
in the measurement of HbA1c, clinicians
should exercise judgment, particularly
when the result is close to the threshold
that might prompt a change in therapy.
HbA1c results may be discrepant from the
patient’s true mean glycemia in certain
racial and ethnic groups, and in condi-
tions that alter red blood cell turnover,
such as anemia, end-stage renal disease
(ESRD) (especially with erythropoietin
therapy), and pregnancy, or if an HbA1c
assay sensitive to hemoglobin variants
is used in someone with sickle cell trait
or other hemoglobinopathy. Discrep-
ancies between measured HbA1c and
measured or reported glucose levels
should prompt consideration that one
of these may not be reliable (12).
Regular self-monitoringofbloodglucose
(SMBG) may help with self-management
and medication adjustment, particularly
in individuals taking insulin. SMBG plans
should be individualized. People with
diabetes and thehealth care teamshould
use the data in an effective and timely
manner. In people with type 2 diabetes
not using insulin, routine glucose mon-
itoring is of limited additional clinical
benefit while adding burden and cost
(13,14). However, for some individuals,
glucose monitoring can provide insight
into the impact of lifestyle and medica-
tion management on blood glucose and
symptoms, particularly when combined
with education and support. Novel tech-
nologies, such as continuous or flash
glucose monitoring, provide more infor-
mation. However, in type 2 diabetes,




c Providers and health care systems
should prioritize the delivery of
patient-centered care.
Providing patient-centered care that
acknowledges multimorbidity, and is
respectful of and responsive to individ-
ual patient preferences and barriers,
including the differential costs of thera-
pies, is essential to effective diabetes
management (16). Shared decision mak-
ing, facilitated by decision aids that
show the absolute benefit and risk of
alternative treatment options, is a useful
strategy to arrive at the best treatment
course for an individual (17–20). Pro-
viders should evaluate the impact of
any suggested intervention, including
self-care regimens, in the context of
cognitive impairment, limited literacy,
distinct cultural beliefs, and individual
fears or health concerns given their
impact on treatment efficacy.
DSMES
Consensus recommendation
c All people with type 2 diabetes
should be offered access to ongo-
ing DSMES programs.
DSMES is a key intervention to en-
able people with diabetes to make
informed decisions and to assume re-
sponsibility for day-to-day diabetes
management. DSMES is central to es-
tablishing and implementing the princi-
ples of care (Fig. 1). DSMES programs
usually involve face-to-face contact in
group or individual sessions with trained
educators, and key components are
shown in Table 1 (21–25). While DSMES
should be available on an ongoing basis,
critical junctures when DSMES should
occur include at diagnosis, annually,
when complications arise, and during
transitions in life and care (22).
DSMES programs delivered from
diagnosis can promote medication
adherence, healthy eating, and physi-
cal activity, and increase self-efficacy.
In type 2 diabetes, high-quality evi-
dence has consistently shown that
DSMES is a cost-effective intervention
in the health care systems studied.
DSMES significantly improves clinical
and psychological outcomes, improves
glycemic control, reduces hospital ad-
missions, improves patient knowledge,
and reduces the risk of all-cause mor-
tality (22,26–31). The best outcomes
are achieved in those programs with a
theory-based and structured curricu-
lum and with contact time of over
10 h. While online programs may re-
inforce learning, there is little evi-
dence they are effective when used
alone (27).
Consensus recommendation
c Facilitating medication adherence
should be specifically considered
when selecting glucose-lowering
medications.
Suboptimal adherence, including poor
persistence, to therapy affects almost
half of people with diabetes, leading
to suboptimal glycemic and cardiovas-
cular disease (CVD) risk factor control as
well as increased risk of diabetes com-
plications, mortality, hospital admis-
sions, and health care costs (32–36).
Though this consensus recommenda-
tion focuses on medication adherence
(including persistence), the principles
are pertinent to all aspects of diabetes
care. Multiple factors contribute to
inconsistent medication use and treat-
ment discontinuation, including patient-
perceived lack of medication efficacy,
fear of hypoglycemia, lack of access
to medication, and adverse effects of
medication (37). Medication adherence
(including persistence) varies across
medication classes and careful consider-
ation of these differences may help im-
prove outcomes (38). Ultimately, patient
preference is a major factor driving the
choice of medication. Even in cases
where clinical characteristics suggest
the use of a particular medication based
on the available evidence from clinical
trials, patient preferences regarding
route of administration, injection de-
vices, side effects, or cost may prevent
their use by some individuals (39).
Therapeutic inertia, sometimes re-
ferred to as clinical inertia, refers to
failure to intensify therapy when treat-
ment targets are not met. The causes
of therapeutic inertia are multifacto-
rial, occurring at the level of the prac-
titioner, patient, and/or health care
system (40). Interventions targeting
therapeutic inertia have facilitated
improved glycemic control and timely
insulin intensification (41,42). For
example, multidisciplinary teams that
include nurse practitioners or pharma-
cists may help reduce therapeutic iner-
tia (43,44). A fragmented health care
system may contribute to therapeutic
inertia and impair delivery of patient-
centered care. A coordinated chronic
care model, including self-management
support, decision support, delivery sys-
tem design, clinical information sys-
tems, and community resources and
policies, promotes interaction between
more empowered patients and better





DOES NEW EVIDENCE FROM
CARDIOVASCULAR OUTCOMES
TRIALS FIT IN?
In prior consensus statements, efficacy
in reducing hyperglycemia, along with
tolerability and safety were primary
factors in glucose-lowering medication
selection. Patient preferences, glycemic
targets, comorbidities, polypharmacy,
side effects, and cost were additional
Table 1—Key components of DSMES (21,23–25)
c Evidence-based
c Individualized to the needs of the person, including language and culture
c Has a structured theory-driven written curriculum with supporting materials
c Delivered by trained and competent individuals (educators) who are quality assured
c Delivered in group or individual settings
c Aligns with the local population needs
c Supports the person and their family in developing attitudes, beliefs, knowledge, and skills to
self-manage diabetes
c Includes core content; i.e., diabetes pathophysiology and treatment options; medication
usage; monitoring, preventing, detecting, and treating acute and chronic complications;
healthy coping with psychological issues and concerns; problem solving and dealing with
special situations (i.e., travel, fasting)
c Available to patients at critical times (i.e., at diagnosis, annually,when complications arise, and
when transitions in care occur)
c Includes monitoring of patient progress, including health status, quality of life
c Quality audited regularly
DSMES is a critical element of care for all people with diabetes and is the ongoing process
of facilitating the knowledge, skills, and ability necessary for diabetes self-care as well as activities
that assist a person implementing and sustaining behaviors needed to manage their
diabetes on an ongoing basis. National organizations in the U.S. and Europe have published
standards to underpin DSMES. In the U.S., these are defined as DSMES “services,” whereas in
Europe they are often referred to as “programs.”Nevertheless, the broad components are similar.
important considerations. For every in-
dividual, the choice of glucose-lowering
medication should be underpinned by
lifestyle management, DSMES, and the
patient-centered care principles outlined
in Fig. 1.
Figure 2 describes our new consensus
approach to glucose lowering with med-
ications in type 2 diabetes. Because of the
new evidence for the benefit of specific
medications to reduce mortality, heart
failure (HF), and progression of renal
disease in the setting of established
CVD, their use was considered compel-
ling in this patient group. Thus, we rec-
ommend that providers consider a
history of CVD very early in the process
of treatment selection. Other factors
affect the choice of glucose-lowering
medications, particularly in the setting
of patient-centered care. In addition to
CVD, we recommend early consideration
of weight, hypoglycemic risk, treatment
cost, and other patient-related factors
that may influence treatment selection
(Figs. 2–6).
Implications of New Evidence From
Cardiovascular Outcomes Trials
The major change from prior consensus
reports is based on new evidence that
specific sodium–glucose cotransporter
2 (SGLT2) inhibitors or glucagon-like
peptide 1 (GLP-1) receptor agonists im-
prove cardiovascular outcomes, as well
as secondary outcomes such as HF and
progression of renal disease, in patients
with established CVD or CKD. Therefore,
an important early step in this new
approach (Fig. 3) is to consider the pres-
ence or absence of ASCVD, HF, and CKD,
conditions inaggregate affecting15–25%
of the population with type 2 diabetes.
While the new evidence supporting the
use of particular medications in patients
who also have established CVD or are at
high risk of CVD is derived from large
cardiovascular outcomes trials (CVOTs)
demonstrating substantial benefits over
2–5 years, it is important to remember
that each trial constitutes a single ex-
periment. Within each drug class, results
have been heterogeneous. It is not clear
whether there are true drug-class ef-
fects with different findings for individ-
ual medications due to differences in
trial design and conduct, or whether
there are real differences between
medications within a drug class due to
properties of the individual compounds.
Where the current evidence is strongest
for a specific medication within a class, it
is noted. The American Diabetes Asso-
ciation’s (ADA) Standards of Medical
Care in Diabetes will align with this
document and will be updated to reflect
newevidenceas it emerges fromongoing
clinical trials.
Consensus recommendation
c Among patients with type 2 diabe-
tes who have established ASCVD,
SGLT2 inhibitors or GLP-1 recep-
tor agonists with proven cardiovas-
cular benefit are recommended
as part of glycemic management
(Figs. 2 and 3).
ASCVD is defined somewhat differ-
ently across trials, but all trials enrolled
individuals with established CVD (e.g.,
myocardial infarction [MI], stroke,
any revascularization procedure) while
variably including related conditions
compatible with clinically significant
atherosclerosis (e.g., transient ischemic
attack, hospitalized unstable angina,
amputation, congestive heart failure
New York Heart Association [NYHA] class
II–III,.50% stenosis of any artery, symp-
tomatic or asymptomatic coronary artery
disease documented by imaging, CKD
with estimated glomerular filtration rate
[eGFR],60mL min21[1.73]22).Most trials
also included a “risk factor only” group
with entry criteria basedon age and usually
the presence of two or more cardiac risk
factors (46). Trials were designed to eval-
uate cardiovascular safety (i.e., statistical
noninferiority comparedwith placebo), but
several showed ASCVD outcome benefit
(i.e., statistical superiority compared with
placebo), including, in somecases,mortality.
Among GLP-1 receptor agonists, lira-
glutide, studied in the Liraglutide
Effect and Action in Diabetes: Evalua-
tion of Cardiovascular Outcome Results
(LEADER) trial (n59,340), demonstrated
an ARR of 1.9% with a hazard ratio (HR)
of 0.87 (95% CI 0.78, 0.97; P 5 0.01 for
superiority) for the primary composite
outcome of cardiovascular death, non-
fatal MI, and nonfatal stroke (major ad-
verse cardiac events [MACE]) compared
with placebo over 3.8 years. Each com-
ponent of the composite contributed to
the benefit, and the HR for cardiovascular
death was 0.78 (95% CI 0.66, 0.93; P 5
0.007; ARR 1.7%). The LEADER trial also
demonstrated an HR of 0.85 (95% CI,
0.74, 0.97; P 5 0.02; ARR 1.4%) for
all-cause mortality (47). In the Trial to
Evaluate Cardiovascular and Other Long-
term Outcomes with Semaglutide in
Subjects with Type 2 Diabetes (SUSTAIN
6) (n 5 3,297), semaglutide compared
with placebo demonstrated an ARR of
2.3% with HR 0.74 for MACE (95% CI 0.58,
0.95; P 5 0.02 for superiority) over 2.1
years, but the reduction in events ap-
peared to be driven by the rate of stroke
rather than CVD death (48). The Exena-
tide Study of Cardiovascular Event Low-
ering (EXSCEL) compared exenatide
extended-release with placebo over
3.2 years in 14,752 participants with
type 2 diabetes. While the medication
was safe (noninferior), the HR for MACE
in the entire trial was 0.91 (95% CI 0.83,
1.0; P5 0.06) not reaching the threshold
for demonstrated superiority versus pla-
cebo; ARRwas 0.8% (49). All-cause death
was lower in the exenatide arm (ARR 1%,
HR 0.86 [95% CI 0.77, 0.97]), but it was
not considered to be statistically signif-
icant in the hierarchical testing proce-
dure applied. Lixisenatide, a short-acting
GLP-1 receptor agonist, did not demon-
strate CVD benefit or harm in a trial of
patients recruited within 180 days of an
acute coronary syndrome admission (50).
Taken together, it appears that among
patientswith established CVD, some GLP-
1 receptor agonists may provide cardio-
vascular benefit, with the evidence of
benefit strongest for liraglutide, favorable
for semaglutide, and less certain for ex-
enatide. There is no evidence of cardio-
vascular benefitwith lixisenatide. Adverse
effects for the class are discussed in the
section “The Full Range of Therapeutic
Options: Lifestyle Management, Medica-
tion, and Obesity Management.”
Among the SGLT2 inhibitors, em-
pagliflozin compared with placebo was
studied in the Empagliflozin, Cardiovas-
cular Outcome Event Trial in Type 2
Diabetes Mellitus Patients (EMPA-REG
OUTCOME) in 7,020 participants with
type 2 diabetes and CVD. With a median
follow-up of 3.1 years, the ARR was 1.6%
and the HR was 0.86 (95% CI 0.74, 0.99;
P5 0.04 for superiority) for the primary
composite end point of nonfatal MI,
nonfatal stroke, and cardiovascular
death. The ARR was 2.2% and the HR
was 0.62 (95% CI 0.49, 0.77; P , 0.001)
for cardiovascular death (51). The ARR
was 2.6% and the HR was 0.68 (95% CI





























































































































Figure 3—Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase
4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Figure 4—Choosing glucose-lowering medication if compelling need to minimize weight gain or promote weight loss. GLP-1 RA, glucagon-like peptide
1 receptor agonist; T2DM, type 2 diabetes; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Figure 5—Choosing glucose-lowering medication if compelling need to minimize hypoglycemia. DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA,
glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor.
Figure 6—Choosing glucose-lowering medication if cost is a major issue. DPP-4i, dipeptidyl peptidase 4 inhibitor; SGLT2i, SGLT2 inhibitor; SU,
sulfonylurea.
any cause. Canagliflozin compared with
placebo was studied in the Canagliflozin
Cardiovascular Assessment Study
(CANVAS) Program (comprised of two
similar trials, CANVAS and CANVAS-
Renal; n 5 10,142) in participants with
type 2 diabetes, 66% of whom had
a history of CVD. Participants were
followed for a median of 3.6 years. In
the combined analysis of the two trials,
the primary composite end point of
MI, stroke, or cardiovascular death was
reduced with canagliflozin (26.9 vs.
31.5 participants per patient-year with
placebo; HR 0.86 [95% CI 0.75, 0.97];
P 5 0.02) for superiority in the pooled
analysis, with consistent findings in
the component studies. Though there
was a trend toward benefit for cardio-
vascular death, the difference from
placebo was not statistically significant
in the CANVAS Program (52). For the
SGLT2 inhibitors studied to date, it ap-
pears that among patientswith established
CVD, there is likely cardiovascular benefit,
with the evidence of benefit modestly
stronger for empagliflozin than canagli-
flozin. Adverse effects for the class
are discussed in the section “The Full
Range of Therapeutic Options: Lifestyle
Management, Medication, and Obesity
Management.”
While the evidence of an ASCVD out-
comes benefit for GLP-1 receptor ago-
nists and SGLT2 inhibitors has been
demonstrated for people with estab-
lished ASCVD, the evidence of benefit
beyond glucose lowering has not been
demonstrated in those without ASCVD.
Indeed, in subgroup analyses of these
trials, lower-risk individuals have not
beenobserved tohave anASCVDbenefit.
While this may be due to the short time
frame of the studies and the low event
rate in those without ASCVD, the finding
is consistent across the reported trials.
Overall, CVOTs of dipeptidyl peptidase
4 (DPP-4) inhibitors have demonstrated
safety, i.e., noninferiority relative to pla-
cebo, for the primary MACE end point,
but not cardiovascular benefit.
The available evidence for cardiovas-
cular event reduction in patients with
type 2 diabetes and clinical CVD is derived
from trials in which the participants were
not meeting glycemic targets (HbA1c
$53 mmol/mol [$7%] at baseline). Fur-
thermore, most (;70% across trials)
participants were treated with metfor-
min at baseline. Thus, we recommend
that patients with clinical CVD not meet-
ing individualized glycemic targets while
treated with metformin (or in whom
metformin is contraindicated or not tol-
erated) should have an SGLT2 inhibitor
or GLP-1 receptor agonist with proven
benefit for cardiovascular risk reduction
added to their treatment program. There
are no clinical trial data that support
prescribing an SGLT2 inhibitor or GLP-
1 receptor agonist with the intent of
reducing cardiovascular risk in patients
with an HbA1c ,53 mmol/mol (,7%).
Limited data suggest that there is no
heterogeneity in the cardiovascular ben-
efits of SGLT2 inhibitors or GLP-1 recep-
tor agonists as a function of background
glucose-lowering therapy. Thus, back-
ground glucose-lowering therapy in pa-
tients with clinical CVD arguably is not
pertinent in clinical decision making.
However, dose adjustment or discontin-
uation of background medications may
be required to avoid hypoglycemia
when adding a new agent to a regi-
men containing insulin, sulfonylurea, or
glinide therapy, particularly in patients at
or near glycemic goals. Full efforts to
achieve glycemic and blood pressure
targets and to adhere to lipid, antiplate-
let, antithrombotic, and tobacco ces-
sation guidelines (7) should continue
after an SGLT2 inhibitor or GLP-1 re-
ceptor agonist is added, as such efforts




c Among patients with ASCVD in
whom HF coexists or is of special
concern, SGLT2 inhibitors are rec-
ommended (Figs. 2 and 3).
Patients with type 2 diabetes are at
increased risk of HF (53). In the EMPA-
REG OUTCOME and CANVAS CVOT stud-
ies testing SGLT2 inhibitors, which
enrolled participants with ASCVD,.85%
of participants did not have symptomatic
HF at baseline. Yet, in both trials there
wasa clinically and statistically significant
reduction in hospitalization for HF for
the SGLT2 inhibitor as compared with
placebo. In the EMPA-REG OUTCOME
study with empagliflozin (54), the ARR
was 1.4%, and the HR 0.65 (95% CI
0.50, 0.85), and in the CANVAS Pro-
gram with canagliflozin, the HR was
0.67 (95% CI 0.52, 0.87), with a rate of
hospitalized HF of 5.5 vs. 8.7 events per
1,000 patient-years (55). Because HF was
neitherwell characterized at baselinenor
as carefully adjudicated as it would have
been in a trial specifically designed to
evaluate HF outcomes, and because HF
was a secondary end point in the trials,
further ongoing studies are required to
conclusively address the issue. That said,
the significant reduction in hospitaliza-
tion for HF demonstrated in the two
study populations and the consistency
across two independent trial programs
suggest to us that treatment with SGLT2
inhibitors in the setting of clinical HF may
provide substantial benefit and should
be specifically considered in people with
type 2 diabetes and ASCVD and HF.
In the GLP-1 receptor agonist studies
LEADER, SUSTAIN 6, and EXSCEL, there
was no significant effect on hospitaliza-
tion for HF with HR 0.86 (95% CI 0.71,
1.06), 1.11 (95% CI 0.77, 1.61), and 0.94
(95% CI 0.78, 1.13), respectively (47–49).
Two short-term studies of liraglutide in
patients with reduced ejection fraction
suggested a lack of benefit in this setting
(56,57).
Among the recent cardiovascular
safety outcomes trials testing DPP-4 in-
hibitors, the Saxagliptin Assessment of
Vascular Outcomes Recorded in Patients
with Diabetes Mellitus–Thrombolysis
in Myocardial Infarction 53 (SAVOR-
TIMI 53) study evaluating saxagliptin
demonstrated a significant increased risk
of HF, with 3.5% risk of hospitalization
for HF versus 2.8% for placebo (HR 1.27;
95% CI 1.07, 1.51; P5 0.007) (58). In the
subsequent Examination of Cardiovascu-
lar Outcomes with Alogliptin versus Stan-
dard of Care (EXAMINE) study of alogliptin
there was no statistically significant dif-
ference in HF hospitalization (3.9% vs. 3.3%
with placebo) (59), and in the Trial Eval-
uating Cardiovascular Outcomes with
Sitagliptin (TECOS), the rate of hospital-
ization for HF was 3.1% in both sitagliptin-
and placebo-treated patients (60).
Consensus recommendation
c For patients with type 2 diabetes
and CKD, with or without CVD,
consider the use of an SGLT2 in-
hibitor shown to reduce CKD pro-
gression or, if contraindicated or
not preferred, a GLP-1 receptor
agonist shown to reduce CKD pro-
gression (Figs. 2 and 3).
Patients with type 2 diabetes and kidney
disease are at an increased risk for car-
diovascular events. A substantial number
of participants with an eGFR of 30–60 mL
min–1 [1.73m]–2 were included in EMPA-
REG OUTCOME, CANVAS, LEADER, and
SUSTAIN 6. An important finding in the
studies was reduction of the primary
ASCVDoutcomeevenamongparticipants
with stage 3 CKD (eGFR 30–60 mL min–1
[1.73m]–2). For SGLT2 inhibitors, this con-
trasts with the glucose-lowering effect,
which diminishes with declining eGFR.
In addition to the primary cardiovas-
cular end points, most of the SGLT2
inhibitor and GLP-1 receptor agonist
CVOTs reported benefit in renal end
points, albeit as secondary outcomes.
The renal outcome benefit has been
most pronounced and consistent for
SGLT2 inhibitors. EMPA-REG OUTCOME
(empagliflozin) demonstrated an ARR
6.1%, HR of 0.61 (95% CI 0.53, 0.70)
for the composite outcome of new or
worsening nephropathy (progression to
urine albumin/creatinine ratio .33.9
mg/mmol [.300 mg/g], doubling of se-
rum creatinine and ESRD, or death by
ESRD). The most prevalent outcome com-
ponent was the development of sustained
albuminuria, but the other components
were each significantly reduced relative
to placebo (61). CANVAS (canagliflozin)
reported an HR of 1.7 (95% CI 1.51, 1.91)
for regression of albuminuria and a 40%
reduction in risk in the composite out-
come of eGFR, ESRD, or renal death (5.5
vs. 9.0 participants per 1,000 patient-
years; HR 0.60; 95% CI 0.47, 0.77) (52).
Additional trials with primary renal end
points are ongoing in high-risk renal
populations. The Evaluation of the Ef-
fects of Canagliflozin on Renal and Car-
diovascular Outcomes in Participants
with Diabetic Nephropathy (CREDENCE)
trial examining canagliflozin in CKD with
proteinuria has been stopped at a planned
interim analysis for achieving the primary
efficacy end point (62).
In LEADER and SUSTAIN 6, the GLP-1
receptor agonist liraglutide was associ-
ated with an ARR of 1.5% and an HR of
0.78 (95% CI 0.67, 0.92) for new or wors-
ening nephropathy (63), and semaglu-
tide demonstrated an ARR of 2.3%
and an HR of 0.64 (95% CI 0.46, 0.88)
for new or worsening nephropathy (48).
Progression of albuminuria was the
most prevalent component of the com-
posite renal end point, whereas the other
components (doubling of serum creati-
nine, ESRD, or renal death) did not con-
tribute substantially to the benefit. In
the DPP-4 inhibitor CVOTs, the DPP-4 in-
hibitors have been shown to be safe
from a renal perspective, with modest





This section summarizes the lifestyle,
medication, and obesity management
therapies that lower glucose or improve
other outcomes in patients with type 2
diabetes. A more comprehensive discus-
sion of these issues is available elsewhere
(3,21,65). Formore details onweight loss
medications and metabolic surgery, see
the section “Obesity Management Beyond
Lifestyle Intervention.” Basic information
about specific options in each category of
therapy is summarized in Table 2.
Lifestyle interventions, including MNT
and physical activity, are effective and
safe for improving glucose control in type
2 diabetes. For these reasons, they are
recommended as first-line therapies from
the time of diagnosis and as cotherapy
for patients who also require glucose-
lowering medications or metabolic sur-
gery. Lifestyle management should be part
of the ongoing discussion with individ-
uals with type 2 diabetes at each visit.
Lifestyle Management
Consensus recommendation
c An individualized program of MNT
should be offered to all patients.
Medical Nutrition Therapy
MNTcompriseseducationandsupport to
help patients adopt healthy eating pat-
terns. The goal of MNT is to manage
blood glucose and cardiovascular risk
factors to reduce risk fordiabetes-related
complications while preserving the plea-
sure of eating (21). Two basic dimensions
ofMNT includedietary quality and energy
restriction. Strategies directed at each
dimension can improve glycemic control.
DietaryQuality andEatingPatterns.There is
no single ratio of carbohydrate, proteins,
and fat intake that is optimal for every
person with type 2 diabetes. Instead,
there are many good options and pro-
fessional guidelines usually recommend
individually selected eating patterns that
emphasize foods of demonstrated health
benefit, that minimize foods of demon-
strated harm, and that accommodate
patient preference andmetabolic needs,
with the goal of identifying healthy di-
etary habits that are feasible and sustain-
able. Three trials of a Mediterranean
eating pattern reported modest weight
loss and improved glycemic control
(66–68). In one of these, people with
new-onset diabetes assigned to a low-
carbohydrate Mediterranean eating pat-
tern were 37% less likely to require
glucose-lowering medications over 4
years compared with patients assigned
to a low-fat diet (HR 0.63 [95% CI 0.51,
0.86]). A meta-analysis of RCTs in pa-
tients with type 2 diabetes showed that
the Mediterranean eating pattern re-
duced HbA1c more than control diets
(mean difference 23.3 mmol/mol, 95%
CI25.1,21.5mmol/mol [20.30%, 95% CI
20.46%,20.14%]) (69). Low-carbohydrate,
low glycemic index, and high-protein diets,
and the Dietary Approaches to Stop Hyper-
tension (DASH) diet all improve glycemic
control, but the effect of the Mediterra-
nean eating pattern appears to be the
greatest (70–72). Low-carbohydrate diets
(,26%of total energy) produce substan-
tial reductions in HbA1c at 3months (25.2
mmol/mol, 95% CI 27.8, 22.5 mmol/mol
[20.47%, 95% CI 20.71%, 20.23%]) and
6months (4.0 mmol/mol, 95% CI 26.8,
21.0 mmol/mol [20.36%, 95% CI 20.62%,
20.09%]), with diminishing effects at 12
and 24 months; no benefit of moderate
carbohydrate restriction (26–45%) was
observed (73). Vegetarian eating pat-
terns have been shown to lower HbA1c,
but not fasting glucose, compared with
nonvegetarian ones (74). Very recent tri-
als of different eating patterns in type 2
diabetes have typically also included
weight reduction, hindering firm con-
clusions regarding the distinct contribu-
tion of dietary quality.
Consensus recommendation
c All overweight and obese patients
with diabetes should be advised of
the health benefits of weight loss
and encouraged to engage in a
program of intensive lifestyle man-
agement, which may include food
substitution.
Nonsurgical Energy Restriction for Weight
Loss. If a patient wishes to aim for re-






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































within 6 years of diagnosis, evidence-
basedweightmanagement programs are
often successful.
The most effective nonsurgical strat-
egies for weight reduction involve food
substitution and intensive, sustained
counseling (e.g., 12–26 individual coun-
seling sessions over 6–12 months).
Among adults with type 2 diabetes,
meal replacement (825–853 kcal/day
[3,450–3,570 kJ/day] formula diet for
3–5 months) followed by gradual rein-
troduction of food and intensive coun-
seling resulted in 9-kg placebo-adjusted
weight loss at 1 year and high rates of
diabetes remission (46% vs. 4%; odds
ratio [OR] 19.7 [95% CI 7.8, 49.8]) com-
pared with best usual practice (75). In
terms of intensive behavioral interven-
tions, the Action for Health in Diabetes
(Look AHEAD) trial (76) randomized
5,145 overweight or obese patients
with type 2 diabetes to an intensive
lifestyle program that promoted energy
restriction, incorporating meal replace-
ments to induce and sustain weight loss,
along with increased physical activity
compared with standard diabetes edu-
cation and support in the control group.
After 9.6 years, weight loss was greater
in the intervention group (8.6% vs. 0.7%
at 1 year; 6.0% vs. 3.5% at study end;
both P , 0.05). HbA1c also fell in the
intervention group despite less use of
glucose-lowering medications. Cardio-
vascular event rates were not reduced,
but there were numerous other bene-
fits. In a 12-month trial, 563 adults with
type 2 diabetes who were randomized
to Weight Watchers compared with stan-
dard care had a 2.1% net weight loss
(24.0% vs. 21.9%; P , 0.001), a 5.3
mmol/mol (23.5 vs. 11.8 mmol/mol;
P5 0.020) net absolute improvement in
HbA1c (0.48% [20.32%vs.10.16%]), and
a greater reduction in use of glucose-
lowering medications (226% vs. 112%;
P , 0.001) (77). Similar programs have




c Increasing physical activity improves
glycemic control and should be en-
couraged in all people with type 2
diabetes.
Aerobic exercise, resistance training, and
the combination of the two are effective
in reducing HbA1c by about 6.6 mmol/mol
(0.6%) (81–84). Of these modalities, some
evidence suggests that aerobic exer-
cise and the combination of aerobic ex-
ercise and resistance training may be
more effective than resistance training
alone (85), but this remains controver-
sial. When considering exercise interven-
tions, special considerations are required
for individuals with CVD, uncontrolled
retinopathy or nephropathy, and severe
neuropathy. A wide range of physical
activity, including leisure time activities
(e.g., walking, swimming, gardening, jog-
ging, tai chi, and yoga) can significantly
reduce HbA1c (86–90). In general, super-
vision of exercise and motivational strat-
egies, such as monitoring using a step
counter, can improve the effect of exer-
cise on HbA1c compared with advice
alone (84,91). The combinationofdietary
change forweight reduction and physical
exercise improves hyperglycemia and
reduces cardiovascular risk factors more
than dietary interventions or physical
activity alone (92).
Medications for Lowering Glucose
Metformin
Metformin is an oral medication that
reduces plasma glucose via multiple mech-
anisms. It is available as an immediate-
release formulation that is typically
administered twice a day and as ex-
tended-release formulations for once-
daily or twice-daily administration. The
formulations are equally effective with
no consistent differences in side effect
profile (93). Dosages of immediate-
release metformin start at 500 mg once
or twice a day with meals and should be
increased as tolerated to a target dosage
of 1,000 mg twice a day. The maximum
daily dose is 2,550 mg in the U.S. and
3,000 mg in the European Union, though
doses above 2,000 mg are generally
associated with little additional efficacy
and poorer tolerability (94). Gastroin-
testinal symptoms are common and
dose dependent, and may improve over
time or with dose reduction. Metformin
should not be used in patients with an
eGFR,30 mL min–1 [1.73 m]–2 and dose
reduction should be considered when
the eGFR is ,45 mL min–1 [1.73 m]–2
(95–97). Caution should be taken when
conditions are present that may re-
duce eGFR. Advantages of metformin
include its high efficacy, low cost, min-
imal hypoglycemia risk when used as
monotherapy, and the potential for
some weight loss. Some studies have
suggested a benefit for preventing
CVD (98), but this has not been supported
by the results of a recent meta-analysis
(99). However,metforminmay lower risk
for cardiovascular mortality compared
with sulfonylurea therapy (100). Rare
cases of lactic acidosis have been re-
ported, usually in the setting of severe
illness or acute kidney injury. Therefore,
metformin should be omitted in the set-
ting of severe illness, vomiting, or de-
hydration. Metforminmay result in lower
serum vitamin B12 concentration; there-
fore, periodic monitoring and supple-
mentation is generally recommended
if levels are deficient, particularly in
those with anemia or neuropathy (101).
Because of its high efficacy in lowering
HbA1c, good safety profile, and low cost,
metformin remains the first-line medica-
tion for management of type 2 diabetes.
SGLT2 Inhibitors
SGLT2 inhibitors are oral medications
that reduce plasma glucose by enhancing
urinary excretion of glucose (102). The
glucose-lowering efficacy of these med-
ications is dependent on renal function.
Initiation and continuation of SGLT2 in-
hibitors are restricted by eGFR and re-
quire intermittent monitoring of renal
function (refer to European Medicines
Agency and U.S. Food and Drug Ad-
ministration prescribing information
for current recommendations). These
medications are of high efficacy in low-
ering glucose in the setting of normal
renal function (51,52,103). All SGLT2 in-
hibitors are associated with a reduction
in weight and blood pressure. Alone or
withmetformin, they do not increase the
risk for hypoglycemia. Empagliflozin and
canagliflozin have cardiac and renal ben-
efits in patients with established or at
high risk of ASCVD. Cardiac and renal
benefits have been demonstrated down
to an eGFR of 30 mL min–1 [1.73 m]–2,
though currently none of the SGLT2
inhibitors have been approved for
use by regulators at an eGFR below
45 mL min–1 [1.73 m]–2 (see the section
“Recommended Process for Glucose-
Lowering Medication Selection: Where
Does New Evidence From Cardiovascular
Outcomes Trials Fit In?”) (51,52,61). The
class is associated with increased risk for
mycotic genital infections (mostly vagi-
nitis in women, balanitis in men) (51,
52,104,105). Case reports of diabetic
ketoacidosis with SGLT2 inhibitors in
type 2 diabetes continue to raise con-
cern, though increased rates have not
been confirmed in large trials (102,106).
Therefore, the SGLT2 inhibitors should
be used with caution and appropriate
patient education should be provided for
those with insulin deficiency. SGLT2 in-
hibitors have been associated with an
increased risk of acute kidney injury,
dehydration, and orthostatic hypoten-
sion; caution should be taken when
SGLT2 inhibitors are used in combina-
tion with diuretics and/or ACE inhibi-
tors and angiotensin receptor blockers.
Canagliflozin has been associated with
increased risk for lower-limb amputa-
tion (6.3 canagliflozin vs. 3.4 per 1,000
patient-years with placebo after 3.1
years; HR 1.97 [95% CI 1.41, 2.75]) (52).
Similarly, fracture risk has been reported
with canagliflozin (15.4 vs. 11.9 partici-
pants with fracture per 1,000 patient-
years; HR 1.26 [95% CI 1.04, 1.52]) (52). It
is uncertain whether amputation and
fractures are class effects.
GLP-1 Receptor Agonists
GLP-1 receptor agonists are currently
delivered by subcutaneous injection.
These medications stimulate insulin se-
cretion and reduce glucagon secretion
in a glucose-dependent manner, im-
prove satiety, and promote weight loss
(107,108). Structural differences among
GLP-1 receptor agonists affect dura-
tion of action, and their formulation
and dosing may affect efficacy for glu-
cose-lowering and weight reduction as
well as side effect profile and cardio-
vascular effects (109). Dulaglutide,
exenatide extended-release, and sema-
glutide are administered once weekly
(108,109). Liraglutide and lixisenatide
are administered once daily, and exena-
tide is available in a twice-daily formu-
lation. GLP-1 receptor agonists have high
glucose-lowering efficacy, but with var-
iation within the drug class (110,111).
Evidence suggests that the effect may
be greatest for semaglutide once weekly,
followed by dulaglutide and liraglutide,
closely followed by exenatide once
weekly, and then exenatide twice daily
and lixisenatide (110,112–116). The short-
acting medications exenatide twice daily
and lixisenatide have greater postpran-
dial effects, at least after the meals with
which they are administered. All GLP-1
receptor agonists reduce weight (110);
the reduction ranges from about 1.5 kg
to 6.0 kg over about 30 weeks of ther-
apy (110,117). Liraglutide and semaglutide
have been shown to improve cardiovas-
cular outcomes (47,48) (see the section
“Recommended Process for Glucose-
Lowering Medication Selection: Where
Does New Evidence From Cardiovascu-
lar Outcomes Trials Fit In?”). The most
common side effects of GLP-1 receptor
agonists are nausea, vomiting, and di-
arrhea, though these tend to diminish
over time. GLP-1 receptor agonists have
minimal risk for hypoglycemia, but may
increase the hypoglycemic potential
of insulin and sulfonylureas when com-
bined with those medications (118).
Contrary to early signals, GLP-1 receptor
agonists do not seem to substan-
tially increase risk for pancreatitis, pan-
creatic cancer, or bone disease (119).
They are associated with increased risk
of gallbladder events (120). Semaglu-
tide was associated with increased ret-
inopathy complications in the SUSTAIN
6 trial (HR1.76, 95%CI 1.11, 2.78), largely
among those with baseline retinopa-
thy who had rapid improvement of
glycemic control (48). While this ob-
servation remains unexplained, this is
also a recognized effect of intensifica-
tion of glycemic control with insulin.
DPP-4 Inhibitors
DPP-4 inhibitors are oral medications that
increase insulin secretion and reduce glu-
cagon secretion in a glucose-dependent
manner. They have moderate glucose-
lowering efficacy (121,122). DPP-4 inhib-
itors are well tolerated, have a neutral
effect on weight, and have minimal risk of
hypoglycemiawhen usedasmonotherapy
(123). When added to sulfonylurea ther-
apy, however, the risk for hypoglycemia is
increased 50% compared with sulfonyl-
urea therapy alone (124). The recom-
mended dose for each DPP-4 inhibitor
is determined and needs to be adjusted
based on renal function; linagliptin is the
exception as it hasminimal renal excretion.
Rare but increased rates of pancreatitis
(125) and musculoskeletal side effects
have been reported (126). CVOTs dem-
onstrated the cardiovascular safety but
no cardiovascular benefit of three DPP-4
inhibitors (saxagliptin, alogliptin, and
sitagliptin) as well as imbalances regard-
ing HF for saxagliptin and alogliptin
(127,128) (see the section “Recommended
Process for Glucose-Lowering Medica-
tion Selection: Where Does New Evi-




and rosiglitazone) are oral medications
that increase insulin sensitivity and are
of high glucose-lowering efficacy (129–
131). TZDs increase HDL-cholesterol
(132,133), and pioglitazone has been
shown to reduce cardiovascular end
points (132,134–138) and hepatic steato-
hepatitis (139), but without conclusive
evidence for benefit. TZDs are associated
with the best evidence among glucose-
lowering medications for glycemic du-
rability (140). However, these notable
benefits must be balanced with safety
concerns regarding fluid retention and
congestive heart failure (136,140,141),
weight gain (132,136,140–142), bone
fracture (143,144), and, possibly, bladder
cancer (145). Lower-dose therapy (e.g.,
pioglitazone 15–30mg) mitigates weight
gain and edema, but the broader ben-
efits and harms of low-dose TZD therapy
have not been evaluated.
Sulfonylureas
Sulfonylureas are oral medications that
lower glucose by stimulating insulin se-
cretion from pancreatic b-cells. They are
inexpensive, widely available, and have
high glucose-lowering efficacy (146).
Sulfonylureas were used as part of the
glucose-lowering regimen in the UK Pro-
spective Diabetes Study (UKPDS) (147)
and Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) (148)
trials, which both demonstrated reduc-
tions in microvascular complications. Sul-
fonylureas are associated with weight
gain and risk for hypoglycemia and down
titration of dose to reduce the risk of
hypoglycemia results in higher HbA1c
(146,149,150). Sulfonylureas are known
to be associated with a lack of durable
effect on glucose lowering (144,151). The
weight gain associated with sulfonyl-
ureas is relatively modest in large cohort
studies and the incidence of severe hy-
poglycemia is lower than with insulin
(152). Important differences among sul-
fonylureas affect both safety and effi-
cacy. Glibenclamide (known as glyburide
in the U.S. and Canada) has a higher risk
of hypoglycemia compared with other
sulfonylureas (153).Glipizide, glimepiride,
and gliclazide may have a lower risk for
hypoglycemia compared with other sul-
fonylureas (152,154). Adverse cardio-
vascular outcomes with sulfonylureas in
some observational studies have raised
concerns, although findings from recent
systematic reviews have found no in-
crease in all-cause mortality compared
with other active treatments (152). As
newer-generation sulfonylureas appear
to confer a lower risk of hypoglycemia
and have favorable cost, efficacy, and
safety profiles, sulfonylureas remain a rea-
sonable choice among glucose-lowering
medications, particularly when cost is an
important consideration. Patient educa-
tion anduse of lowor variable dosingwith
later generation sulfonylureas may be
used to mitigate the risk of hypoglyce-
mia. Greatest caution in this regard is
warranted for people at high risk of
hypoglycemia, such as older patients
and those with CKD.
Insulin
Numerous formulations of insulin are
available with differing durations of ac-
tion. Human insulins (NPH, regular [R],
and premixed combinations of NPH and
R) are recombinant DNA-derived human
insulin, while insulin analogs have been
designed to change the onset or duration
of action. The main advantage of insulin
over other glucose-loweringmedications
is that insulin lowers glucose in a dose-
dependent manner over a wide range, to
almost any glycemic target as limited by
hypoglycemia. Older formulations of in-
sulin have also demonstrated reduction
in microvascular complications and with
long-term follow-up, all-cause mortality,
and diabetes-related death (147,155).
Beyond hypoglycemia, the disadvan-
tages of insulin include weight gain and
the need for injection, frequent titration
for optimal efficacy, and glucose moni-
toring (156).
The effectiveness of insulin is highly
dependent on its appropriate use; pa-
tient selection and training; adjustment
of dose for changes in diet, activity, or
weight; and titration to acceptable,
safe glucose targets. Formulations of
intermediate- and long-acting insulin
have different timings of onset, durations
of action, and risks of hypoglycemia.
However, the way in which insulin is ad-
ministered, including the dose, timing
of injection, and glycemic targets, has a
greater impact on the adverse effects of
insulin than differences among insulin
formulations.
Basal Insulin. Basal insulin refers to
longer-acting insulin that is meant to
cover the body’s basal metabolic insulin
requirement (regulating hepatic glucose
production), in contrast to bolus or pran-
dial insulin, which is meant to reduce
glycemic excursions after meals. Basal
insulin is the preferred initial insulin
formulation in patients with type 2
diabetes. Options include once- or twice-
daily administration of intermediate-
acting NPH or detemir insulin and the
once-daily administration of glargine
(U100 or U300) or degludec (U100 or
U200). Long-acting insulin analogs (de-
gludec [U100 or U200], glargine [U100
and U300], detemir) have a modestly
lower absolute risk for hypoglycemia com-
pared with NPH insulin, but cost more
(157–160). However, in real-world set-
tings where patients are treated to con-
ventional treatment targets, initiation of
NPH compared with determir or glargine
U100 did not increase hypoglycemia-
related emergency department visits or
hospital admissions (161). When com-
paring human and analog insulins, cost
differences can be large while differ-
ences in hypoglycemia risk are mod-
est and differences in glycemic efficacy
minimal.
Degludec is associated with a lower
risk of severe hypoglycemia compared
with glargine U100 insulin when target-
ing intensive glycemic control in patients
with long-standing type 2 diabetes at
high risk of CVD; absolute incidence
difference of 1.7% over 2 years (rate
ratio 0.60; P , 0.001 for superiority;
OR 0.73; P , 0.001 for superiority)
(162). Biosimilar formulations are now
available for glarginewith similar efficacy
profile and lower cost (163). No insulin
has been shown to reduce risk for CVD
(156), but data suggest that glargine
U100 and degludec do not increase
risk for MACE (162,164).
Concentrated formulations of de-
gludec (U200) and glargine (U300) are
available that allow injection of a re-
duced volume, a convenience for patients
on higher doses. Glargine U300 is asso-
ciated with a lower risk of nocturnal
hypoglycemia compared with glargine
U100 but requires a 10–14% higher
dose of glargine for equivalent efficacy
(165–167).
Not all patients have their blood glu-
cose adequately controlled with basal
insulin. In particular, patientswith higher
pretreatment HbA1c, higher BMI, longer
duration of disease, and a greater num-
ber of oral glucose-loweringmedications
are more likely to require intensified
therapy (168).
Other Insulin Formulations. Short- and
rapid-acting insulin formulations admin-
istered at mealtime are generally used
to intensify basal insulin therapy in
patients not meeting glycemic targets.
Options include human regular insulin,
various analogs (aspart, glulisine, and
lispro), formulations (faster insulin as-
part, lispro U200), biosimilars (lispro),
and insulins with different routes of
administration (inhaled). Rapid-acting
insulin analogs have a modestly lower
risk for hypoglycemia compared with
human regular insulin but at a higher
cost. Various premixed formulations of
human and analog insulins are available
and continue to be widely used in some
regions, though they tend to have an
increased risk of hypoglycemia as com-
pared with basal insulin alone (Table 2
and Fig. 7).
Other Glucose-Lowering Medications
Other oral glucose-lowering medications
(i.e., meglitinides, a-glucosidase inhibitors,
colesevelam, quick-release bromocriptine,
pramlintide) are not used commonly in
theU.S. and some are not licensed at all in
Europe. No major new scientific informa-
tion on these medications has emerged
in recent years. Their basic characteristics
are listed in Table 2.
Obesity Management Beyond Lifestyle
Intervention
Medications for Weight Loss
Several clinical practice guidelines rec-
ommend weight-loss medications as
an optional adjunct to intensive lifestyle
management for patients with obesity,
particularly if they have diabetes
(169–171). Others do not (172). Several
medications and medication combina-
tions approved in the U.S. or Europe
for weight loss have been found to
improve glucose control in people with
diabetes (173,174). One glucose-lowering
medication, liraglutide, is also ap-
proved for the treatment of obesity
Figure 7—Intensifying to injectable therapies. FRC, fixed-ratio combination; GLP-1 RA, glucagon-like peptide 1 receptor agonist; FBG, fasting blood
glucose; FPG, fasting plasma glucose; max, maximum; PPG, postprandial glucose.
at a higher dose (175). Cost, side effects,
and modest efficacy limit the role of




c Metabolic surgery is a recommended
treatment option for adults with
type 2 diabetes and 1) a BMI
$40.0 kg/m2 (BMI $37.5 kg/m2
in people of Asian ancestry) or 2)
a BMI of 35.0–39.9 kg/m2 (32.5–
37.4 kg/m2 in people of Asian an-
cestry) who do not achieve durable
weight loss and improvement in
comorbidities with reasonable non-
surgical methods.
Metabolic surgery is highly effective in
improving glucose control (176–178)
and often produces disease remission
(179–182). The effects can be sustained
for at least 5 years (177,182). Benefits
include a reduction in the number of
glucose-lowering medications needed to
achieve glycemic targets (178,179).
Several clinical practice guidelines
and position statements recommend
consideration of metabolic surgery
as a treatment option for adults with
type 2 diabetes and 1) a BMI $40.0
kg/m2 (BMI $37.5 kg/m2 in people of
Asian ancestry) or 2) a BMI of 35.0–
39.9 kg/m2 (32.5–37.4 kg/m2 in people
of Asian ancestry) who do not achieve
durable weight loss and improvement in
comorbidities with reasonable nonsurgi-
cal methods (65,183). Because baseline
BMI does not predict surgical benefits on
glycemia or hard outcomes and the im-
provement inglycemic controloccursearly
through weight-independent mechanisms
(183), metabolic surgerymay be considered
for those with a BMI of 30.0–34.9 kg/m2
(27.5–32.4 in people of Asian ancestry)
who do not achieve durable weight loss
and improvement in comorbidities with
reasonable nonsurgical methods.
Adverse effects of bariatric surgery,
which vary by procedure, include surgical
complications (e.g., anastomotic or sta-
ple line leaks, gastrointestinal bleeding,
intestinal obstruction, the need for re-
operation), late metabolic complications
(e.g., protein malnutrition, mineral defi-
ciency, vitamin deficiency, anemia, hypo-
glycemia), and gastroesophageal reflux
(184,185). Patients who undergo meta-
bolic surgerymay be at risk for substance
use, including drug and alcohol use and
cigarette smoking (186). People with
diabetes presenting for metabolic sur-
gery also have increased rates of depres-
sion and other major psychiatric disorders
(187). These factors should be assessed
preoperatively and during follow-up. Met-
abolic surgery should be performed in
high-volume centers with multidisciplin-
ary teams that are experienced in the
management of diabetes and gastrointes-
tinal surgery. Long-term lifestyle support
and routine monitoring of micronutrient
and nutritional status must be provided
to patients after surgery (188,189).
PUTTING IT ALL TOGETHER:
STRATEGIES FOR
IMPLEMENTATION
For an increasing number of patients,
presence of specific comorbidities (e.g.,
ASCVD, HF, CKD, obesity), safety con-
cerns (e.g., risk of hypoglycemia), or health
care environment (e.g., cost of medica-
tions) mandate a specific approach to
the choice of glucose-lowering medica-
tion. These are considered in Figs. 2–6.
For patients not reaching their target
HbA1c, it is important to re-emphasize
lifestyle measures, assess adherence, and
arrange timely follow-up (e.g., within
3–6 months) (Fig. 1).
Initial Monotherapy
Consensus recommendation
c Metformin is the preferred initial
glucose-lowering medication for
most people with type 2 diabetes.
Metformin remains the preferred option
for initiating glucose-lowering medica-
tion in type 2 diabetes and should be
added to lifestyle measures in newly
diagnosed patients. This recommenda-
tion is based on the efficacy, safety,
tolerability, low cost, and extensive
clinical experience with this medication.
Results from a substudy of UKPDS (n 5
342) showed benefits of initial treatment
with metformin on clinical outcomes
related to diabetes, with less hypoglyce-
mia and weight gain than with insulin or
sulfonylureas (98).
Initial Combination Therapy
Compared With Stepwise Addition of
Glucose-Lowering Medication
Consensus recommendation
c The stepwise addition of glucose-
lowering medication is generally
preferred to initial combination
therapy.
In most patients, type 2 diabetes is a
progressive disease, a consequence gen-
erally attributed to a steady decline of
insulin secretory capacity. The practical
impact of gradual loss ofb-cell function is
that achieving a glycemic target with
monotherapy is typically limited to sev-
eral years. Stepwise therapy (i.e., adding
medications to metformin to maintain
HbA1c at target) is supported by clinical
trials (3).While there is some support for
initial combination therapy due to the
greater initial reduction of HbA1c than
can be provided by metformin alone
(190,191), there is little evidence that
this approach is superior to sequential
addition of medications for maintaining
glycemic control or slowing the progres-
sion of diabetes. However, since the
absolute effectiveness of most oral med-
ications rarely exceeds an 11 mmol/mol
(1%) reduction in HbA1c, initial combi-
nation therapy may be considered in
patients presenting with HbA1c levels
more than 17 mmol/mol (1.5%) above
their target. Fixed-dose formulations can
improve medication adherence when
combination therapy is used (192), and
may help achieve glycemic targets more
rapidly (100). Potential benefits of com-
bination therapy need to be weighed
against the exposure of patients to mul-
tiple medications and potential side ef-
fects, increased cost, and, in the case of





c The selection of medication added
to metformin is based on patient
preference and clinical character-
istics. Important clinical charac-
teristics include the presence of
established ASCVD and other co-
morbidities such as HF or CKD; the
risk for specific adversemedication
effects, particularly hypoglycemia
and weight gain; as well as safety,
tolerability, and cost (Figs. 2–6).
As detailed in the “Medications for Low-
ering Glucose” section, the glucose-
lowering medications that can be added
to metformin have distinct profiles of
action, efficacy, and adverse effects
(100,193). The early introduction of basal
insulin is well established, in particu-
lar when HbA1c levels are very high
(.97 mmol/mol [.11%]), symptoms
of hyperglycemia are present, or there
is evidence of ongoing catabolism (e.g.,
weight loss). This constellation of symp-
toms can occur in type 2 diabetes but
suggest insulin deficiency and raise the
possibility of autoimmune (type 1) or
pancreatogenic diabetes in which insu-
lin would be the preferred therapy.
While this remains the usual strategy
for patients when HbA1c levels are very
high, SGLT2 inhibitors (194) and GLP-1
receptor agonists (195) have demon-
strated efficacy in patients with HbA1c
levels exceeding 75 mmol/mol (9%), with
the additional benefits of weight reduc-
tion and reduced risk of hypoglycemia.
Evidence from clinical trials supports
the use of several of the SGLT2 inhibitors
and GLP-1 receptor agonists as add-on
therapy for people with type 2 diabetes
withanHbA1c.53mmol/mol (.7%)and
established CVD (48,51,52). However,
since only 15–20% of patients with
type 2 diabetes conform to the charac-
teristics of patients in these trials, other
clinical features need to be considered
in the majority when selecting second
medications to add to metformin (Figs.
2–6) (149,196–204).
Sulfonylureas and insulin are associ-
ated with an increased risk for causing
hypoglycemia and would not be pre-
ferred for patients in whom this is a
concern. Furthermore, hypoglycemia is
distressing and somay reduce treatment
adherence (Fig. 5). For patients prioritiz-
ing weight loss or weight maintenance
(Fig. 4), important considerations include
the weight reduction associated with
SGLT2 inhibitors and GLP-1 receptor
agonists, the weight neutrality of DPP-4
inhibitors, and the weight gain associ-
ated with sulfonylureas, basal insulin,
and TZDs. An important consideration
for society in general and for many
patients in particular is the cost of
medications; sulfonylureas, pioglita-
zone, and recombinant human insulins
are relatively inexpensive, although
their cost may vary across regions.
Short-term acquisition costs, longer-
term treatment cost, and cost-effective-
ness should be considered in clinical





c Intensification of treatment be-
yond dual therapy to maintain
glycemic targets requires consider-
ation of the impact of medication
side effects on comorbidities, as
well as the burden of treatment
and cost.
The lack of a substantial response to one
or more noninsulin therapies should
raise the issue of adherence and, in those
with weight loss, the possibility that the
patient has autoimmune (type 1) or
pancreatogenic diabetes. However, it
is common in people with long-standing
diabetes to require more than two
glucose-lowering agents, often including
insulin. Compared with the knowledge
base guiding dual therapy of type 2 di-
abetes, there is less evidence guiding
these choices (205). In general, inten-
sification of treatment beyond two
medications follows the same general
principles as the addition of a second
medication, with the assumption that the
efficacy of third and fourth medications
will be generally less than expected.
No specific combination has demon-
strated superiority except for those
that include insulin and GLP-1 receptor
agonists that have broad ranges of gly-
cemic efficacy. As more medications
are added, there is an increased risk
of adverse effects. It is important to
consider medication interactions and
whether regimen complexity may be-
come an obstacle to adherence. Finally,
with each additional medication comes
increased costs, which can affect patient
burden,medication-taking behavior, and
medication effectiveness (193,205–211).
While most patients require intensi-
fication of glucose-lowering medica-
tions, some require medication reduction
or discontinuation of medication, partic-
ularly if the therapy is ineffective or is
exposing patients to a higher risk of side
effects such as hypoglycemia or when
glycemic goals have changed due to a
change in clinical circumstances (e.g.,
development of comorbidities or even
healthy aging). A guiding principle is that
for all therapies the response should be
reviewed at regular intervals, including
the impact on efficacy (HbA1c, weight)
and safety; the therapy should be
stopped or the dose reduced if there are
minimal benefits or if harm outweighs
any benefit. In particular, ceasing or reduc-
ing the dose of medications that have
an increased risk of hypoglycemia is im-
portant when any new glucose-lowering
treatment (lifestyle or medication) is
started (Fig. 7) (40). HbA1c levels below
48 mmol/mol (6.5%) or substantially be-
low the individualized glycemic target
should prompt consideration of stopping
or reducing the dose of medications with
risk of hypoglycemia or weight gain.
Addition of Injectable Medications
Consensus recommendation
c In patients who need the greater
glucose-lowering effect of an in-
jectable medication, GLP-1 recep-
tor agonists are the preferred
choice to insulin. For patients
with extreme and symptomatic hy-
perglycemia, insulin is recom-
mended (Fig. 7).
See the “Insulin” and “Basal Insulin”
sections in “Medications for Lowering
Glucose” for more medication details.
Patients often prefer combinations of
oral medications to injectable medications.
The range of combinations available with
current oral medications allows many peo-
ple to reach glycemic targets safely. How-
ever, there is currently no evidence that
any single medication or combination has
durable effects and, for many patients, in-
jectable medications become necessary
within 5–10 years of diabetes diagnosis.
Evidence from trials comparing GLP-1
receptor agonists and insulin (basal, pre-
mixed, or basal-bolus) shows similar or
even better efficacy in HbA1c reduction
(212,213). GLP-1 receptor agonists
have a lower risk of hypoglycemia and
are associated with reductions in body
weight compared with weight gain with
insulin (212,214). Some GLP-1 receptor
agonists allow for once-weekly injec-
tions, as opposed to daily or more often
for insulin. Based on these consider-
ations, a GLP-1 receptor agonist is the
preferred option in a patient with a def-
inite diagnosis of type 2 diabetes who
needs injectable therapy. However, the
tolerability and high cost of GLP-1 re-
ceptor agonists are important limita-
tions to their use. If additional glucose
lowering is needed despite therapy with
a long-acting GLP-1 receptor agonist, the
addition of basal insulin is a reason-
able option (215,216).
Alternatively, the addition of insulin to
oral medication regimens is well estab-
lished. In particular, using basal insulin
in combination with oral medications is
effective, and has less hypoglycemia and
weight gain than combinations using
premixed insulin formulations or pran-
dial insulin (217). A standard approach
for optimizing basal insulin regimens is
to titrate the dose based on a target fast-
ing glucose concentration, which is a sim-
ple index of effectiveness. Either NPH
insulin or long-acting insulin analogs are
efficacious for controlling fasting glu-
cose, although basal analog formulations
show reduced risks of hypoglycemia,
particularly overnight, when titrated to




c Patients who are unable to main-
tain glycemic targets on basal in-
sulin in combination with oral
medications can have treatment
intensified with GLP-1 receptor ag-
onists, SGLT2 inhibitors, or prandial
insulin (Figs. 7 and 8).
It has become common practice to ap-
proach insulin use in people with type 2
diabetes by following the established
paradigms developed for those with
type 1 diabetes. This includes multiple
daily injections with doses of insulin
analogs before meals that are adjusted
based on ambient blood glucose and
meal constituents. While this is reason-
able for people with type 2 diabetes
who are lean, insulinopenic, and sensi-
tive to exogenous insulin, it ignores the
substantial differences in pathophysiol-
ogy between most people with type 2
diabetes and type 1 diabetes. Most peo-
ple with type 2 diabetes are obese and
insulin resistant, requiring much larger
doses of insulin and experiencing lower
rates of hypoglycemia than those with
type 1 diabetes. In patients with type 2
diabetes, weight gain is a particularly
problematic side effect of insulin use.
Recent evidence supports the effective-
ness of combinations of insulin with
glucose-lowering medications that do
not increase body weight. For example,
SGLT2 inhibitors can be added to insulin
regimens to lower blood glucose levels
without increasing insulin doses, weight
gain, or hypoglycemia (219–221). In a
meta-analysis that studied the combi-
nation of either SGLT2 inhibitors or DPP-
4 inhibitors with insulin, the SGLT2
inhibitor–insulin combination was associ-
ated with a greater reduction in HbA1c,
an advantage in terms of body weight
and no increase in the rates of hypo-
glycemia (222,223). Depending on
baseline HbA1c, glycemic profile, and
individual response, the insulin dose
may need to be reduced to prevent
hypoglycemia when adding an SGLT2
inhibitor.
The combination of basal insulin and
a GLP-1 receptor agonist has high effi-
cacy, with recent evidence from clinical
trials demonstrating the benefits of
this combination to lower HbA1c and
limit weight gain and hypoglycemia
compared with intensified insulin reg-
imens (224,225). Most data come from
studies in which a GLP-1 receptor ago-
nist is added to basal insulin. However,
there is evidence that insulin added to a
GLP-1 receptor agonist can also effectively
lower HbA1c, although some weight gain
results (215). Fixed-ratio combinations
of insulin and GLP-1 receptor agonists
are available and can decrease the
number of injections compared with
administering the medications sepa-
rately (226–228).
A final approach to glycemic manage-
ment when basal insulin plus oral med-
ications is insufficient to achieve HbA1c
targets is intensified insulin regimens
(Figs. 7 and 8). DSMES focused on insulin
therapy is particularly helpful when in-
tensified insulin therapy is considered.
Referral to a diabetes specialist team
should be considered in cases where
the provider is uncomfortable or unfa-
miliar with intensification, poor out-
comes continue despite intensification,
or patients have other issues that com-
plicate intensification. Intensified insulin
regimens include 1) one or more daily
injections of rapid- or short-acting insulin
before meals (prandial insulin) or 2)
switching to one to three daily admin-
istrations of afixed combination of short-
and long-acting insulin (premixed or
biphasic insulins) (229,230). When adding
prandial insulin, giving one injection with
the largest meal of the day is a simple and
safe approach (231). Over time, if glyce-
mic targets are not met with one dose of
prandial insulin daily, additional prandial
injections can be added to other meals
(232). Results of meta-analyses suggest
a modestly greater reduction in HbA1c
with basal-prandial regimens com-
pared with biphasic insulin regimens,
but at the expense of greater weight
gain (233–235). While still commonly
used, we do not generally advocate
premixed insulin regimens, particularly
those administered three times daily,
for routine use when intensifying insulin
regimens (Fig. 7).
Continuous insulin infusion using in-
sulin pumps may have a role in a small




c Access, treatment cost, and in-
surance coverage should all be
considered when selecting glucose-
lowering medications.
The availability of glucose-lowering
medications, patient support systems,
and blood glucose-monitoring devices
can differ worldwide, depending on a
region’s economy, culture, and health
care system. Cost of and access to newer
medications and insulin remain impor-
tant issues throughout the world. Al-
though the economics of diabetes care
is complex and broadly includes the costs
to society of diabetic complications and
long-term outcomes, the cost of drugs
and the affordability of treatment are
often the primary basis for decision
making. Within health care systems, var-
iance in medication coverage is based on
different assessments of cost-effectiveness.
This results in huge disparities in the
cost of new and old glucose-lowering
medications in some countries, limiting
access to the full range of diabe-
tes therapies in large segments of the
population, and creating a two-tiered
system of treatment. Since glycemic
management remains a cornerstone of
the prevention of diabetes complica-
tions, these disparities raise questions
of fairness, equity, and overall public
health. Nonetheless, the use of less
expensive agents, such as metformin,
sulfonylureas, andhuman insulin, remain
effective options (Figs. 2 and 6). Redou-
bling lifestyle management efforts can
also have great impact, but behavioral
intervention and support can also be
costly, and socioeconomic barriers to
improving lifestyle are well described
(237).
Emerging Technology
There is an increasing call for the use of
technology and telemedicine to improve
patients’ health (238). Many types of
inputs can be digitalized, such as blood
glucose levels, time spent exercising,
steps walked, energy ingested, medica-
tion doses administered, blood pressure,
and weight. Patterns in these variables
can be identified by software, leading
to specific treatment recommendations
supported by real-time algorithms.
Telemedicine incorporates multiple types
of communication services, such as two-
way video, e-mail, texting, smartphones,
tablets, wireless monitors, decision sup-
port tools, and other forms of telecom-
munication technologies. Results overall
suggest a modest improvement in glyce-
mic control (239,240).
KEY KNOWLEDGE GAPS
Despite over 200 years of research on
lifestyle management of diabetes and
more than 50 years of comparative-
effectiveness research in diabetes,
innumerable unanswerecd questions
regarding the management of type 2
diabetes remain. In the context of
our current consensus recommenda-
tions, the following is an incomplete
Figure 8—Considering oral therapy in combinationwith injectable therapies. DKA, diabetic ketoacidosis; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1
RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
discussion of vexing issues that must be
addressed.
Evolving areas of current investiga-
tion will provide improvements in dia-
betes care and hold great hope for new
treatments.
c Implementation science. The tools
available to prevent and treat diabetes
are vastly improved. However, imple-
mentation of effective innovation has
lagged behind.
c Basic science. Our understanding of
the basic mechanisms of diabetes, the
development of complications, and
the treatment of both, though contin-
uously advancing, has highlighted how
much we do not know.
c Personalized/precision medicine.
Though promising, these –omics and
big data approaches addressing both
personal and environmental factors
and their interaction are largely un-
realized in diabetes care and will
require large investments and coordi-
nation to have impact.
c Informatics. The benefits and role
of enhanced monitoring of glucose
and other variables leveraged with
real-time informatics-based approaches
to adapt treatment on an individual
basis has great potential but has not
been elucidated.
c Overweight/obesity. Current therapy
is clearly inadequate. Innovation in
methods and implementation would
transform diabetes prevention and
care. Understanding the biology, psy-
chology, and sociology of obesity to
identify pharmacological, behavioral,
and political approaches to preventing
and treating this principal cause of
type 2 diabetes is essential.
c Lifestyle management and DSMES.
Though the benefits of these ap-
proaches are clear, better paradigms
on how to target, individualize, and
sustain the effects are needed.
c b-Cell function. Preserving and en-
hancing b-cell function is perceived
as the holy grail of diabetes and yet
effective techniques are inadequately
developed.
c Translational research. There is a huge
gap between the knowledge gained
from clinical trials and application of
that information in clinical practice.
This gap should be filled with prag-
matic studies and other designs that
include costs, measures of patient
preference, and other patient-recorded
outcome measures. Patients and other
stakeholders should have more input
into trial designs and outcomes. Prag-
matic designs will enhance generaliz-
ability of results and reduce cost.
Better application of “real-world ev-
idence”will complement randomized
trial evidence.
c Drug development. New medications
will require demonstration of broad
efficacy for glucose, comorbidities
and/or complications, aswell as safety
and tolerability to compete in the
marketplace.
c Complications. Steatohepatitis, HF,
nonalbuminuric CKD, chronic mental
illness, and other emerging issues are
complications in diabetes that may
supplant classical microvascular and
macrovascular disease in importance
and impact. Understanding optimal
diagnostic, screening, and treatment
strategies is urgently needed.
Other areas of importance include bet-
ter segmentation of “type 2 diabetes,” as
well as appropriate diagnosis of second-
ary diabetes, which should allow more
informed individualization of care. Better
data on optimal approaches to diabetes
management in frail and older adult
patients is urgently required considering
the controversy around glycemic targets
and the benefits and harms of specific
treatments from lifestyle management
to medications. Current approaches to the
management of type 2 diabetes in ado-
lescents and young adults do not seem to
alter the loss ofb-cell function andmost
individuals in this age-group quickly
transition to insulin therapy. Studies
to guide optimal therapy in this emerging
population with a terrifyingly high risk of
early disability is an immediate need.
There are enduring questions that
continue to challenge guideline develop-
ment. For example, does metformin pro-
vide cardiovascular benefit in patients
with type 2 diabetes early in the natural
history of diabetes, as suggested by the
UKPDS? Is metformin’s role as first-line
medication management truly evidence-
based or a quirk of history? Though the
rationale for early combination therapy
targeting normal levels of glycemia in
early diabetes is seductive, clinical trial
evidence to support specific combina-
tions and targets is essentially nonexis-
tent. As the cost implications for these
approaches is enormous, evidence is des-
perately needed. Different models of
care are being implemented globally.
Defining optimal cost-effective approaches
to care, particularly in the management
of patients (multimorbidity), is essential.
New questions arise from the recent
cardiovascular outcomes studies. Do
the cardiovascular and renal benefits of
SGLT2 inhibitors and GLP-1 receptor ag-
onists demonstrated in patients with
established CVD extend to lower-risk
patients? Is there additive benefit of
use of GLP-1 receptor agonists and
SGLT2 inhibitors for prevention of car-
diovascular and renal events? If so, in
what populations?
Addressing these and other vital clin-
ical questions will require additional in-
vestment in basic, translational, clinical,
and implementation research. More
time- and cost-efficient research para-
digms to address patient-centered end
points will need to be developed through
regulatory reform and leveraging infor-
matics and coordinated learning health
care systems. The increasing burden of
cardiorenal metabolic disease in terms
of incidence, prevalence, and cost is
an existential threat to society. Urgent
attention to improve prevention and
treatment is of the essence.
The management of hyperglycemia in
type 2 diabetes has become extraor-
dinarily complex with the number of
glucose-lowering medications now avail-
able. Patient-centered decision making
and support and consistent efforts to
improve diet and exercise remain the
foundation of all glycemic management.
Initial use of metformin, followed by
addition of glucose-lowering medications
based on patient comorbidities and con-
cerns is recommended as we await an-
swers to themany questions that remain.
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